Key Benefits
Cardiovascular health
Bone mineral density maintenance
Lower incidences of fractures
Better energy and athletic performance
FIND IT IN
Product Specifications
- All natural K2-7
- Fermented from Chickpeas
- Extracted in India
Why do we choose this brand
Years of extensive research on vitamin K2 from production to clinical usage.
Has a proprietary and completely unique method of extracting vitamin K2-7.
3 Patent pending application and 2 in extraction process of K2-7.
Safe to take daily.
Independently verified by 2 credited labs for highest level of quality and reliability.
MenaquinGold was developed with the pharmaceutical process rigor. This fact means that every aspect of development is regulated and validated by a third party lab and by government authorities.
Unsurpassed stability. Proprietary extraction method prevents the accumulation of metabolites that affect the long-term stability. MenaquinGold® has been studied for both long-term and accelerated stability.
The ingredient is characterised. Ingredient characterisation results in consistency in manufacturing, stability and efficacy, and shelf-life testing.
Broad Spectrum of protection and benefits.
BROAD EXTRACTION PROCESS
- Non-GMO chickpeas are fermented in a submerged tank with a bacillus species.
- It is then concentrated using cross flow procedure.
- Solvent extraction process to achieve the highest concentrations of vitamin K2 with a minimum of by-products.
- The K2 is powdered using a gentle vacuum drying process ready for encapsulation.
Tested For
- Heavy Metals
- Microbiological Contamination
- Residual solvents
CERTIFIED AS
- Non-Irradiation
- Patented Pending
- Kosher
- Halal
- Non-Allergen
- Gluten Free
- non-GMO
CLINICAL STUDIES
BIBLIOGRAPHY
Tamatani M, Morimoto S, Nakajima M, Fukuo K, Onishi T, Kitano S, Niinobu T, Ogihara T: Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men. Metabolism 1998, 47(2):195-199.
Study Outcome: Vitamin K1 and MK-7 were significantly, positively correlated with bone mineral density.
Kanai T, Takagi T, Masuhiro K, Nakamura M, Iwata M, Saji F: Serum vitamin K level and bone mineral density in post-menopausal women. Int J Gynaecol Obstet 1997, 56(1):25-30.
Study outcome: The study showed low bone mineral density (BMD) in women with lower serum vitamin K1 and K2.
Hodges SJ, Pilkington MJ, Stamp TC, Catterall A, Shearer MJ, Bitensky L, Chayen J: Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone 1991, 12(6):387-389.
Study outcome: The study showed Vitamin K2 may be up to 25 times more active than vitamin K1. The study of 29 patients with fracture, 17 controls, concluded that vitamin K1 and K2 were significantly lower in the fracture group than in the control group.
Craciun AM, Wolf J, Knapen MH, Brouns F, Vermeer C: Improved bone metabolism in female elite athletes after vitamin K supplementation. Int J Sports Med 1998, 19(7):479-484.
Study outcome: All 8 female marathon runners’ increased vitamin K was associated with an increased calcium-binding capacity of osteocalcin. In the low-estrogen group, vitamin K supplementation induced a 15-20% increase of bone formation markers and a parallel 20- 25% decrease of bone resorption markers.
Sokoll LJ, Booth SL, O'Brien ME, Davidson KW, Tsaioun KI, Sadowski JA: Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma- carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr 1997, 65(3):779-784.
Study outcome: The study showed a significant reduction in undercarboxylated osteocalcin (ucOC) with vitamin K supplementation.
Tsugawa N, Shiraki M, Suhara Y, Kamao M, Ozaki R, Tanaka K, Okano T: Low plasma phylloquinone concentration is associated with high incidence of vertebral fracture in Japanese women. J Bone Miner Metab 2008, 26(1):79-85.
Study outcome: The study carried out in a cohort of 379 healthy women aged 30-88 years showed a significantly higher incidence of vertebral fracture of 14.4% in the low vitamin K group to 4.2 % in the high vitamin K group.
Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15:515-521.
Study outcome: In a randomized, open-label study, 241 osteoporotic women were given either 45 mg/day vitamin K2 or 150 mg elemental calcium (treatment group; n=120) or 150 mg elemental calcium (control group; n=121). After two years, vitamin K2 was shown to maintain lumbar BMD. Patients receiving K2 also experienced significantly lower fracture incidence (10% versus 30%, in the treatment and control groups, respectively.
Marieke et al. The effect of menaquinone7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children'. British Journal of Nutrition October 2009,102 (08):1171-1178
Study outcome: Supplementation with K2-MK-7 for 8 weeks reduces the amount of circulating ucOC and thereby improves vitamin K status in healthy prepubertal children.
Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis 2000;30(6):298-307.
Study outcome: Study showed that vitamin K2 is up to 10 times more bioavailable than K1. Plus, vitamin K2 remains biologically active in the body far longer than K1.